Products
Itanistomig Biosimilar Bispecific Antibody (PD-L1 × CD47) for Research
Cat No.: GMP-Bios-INN-1243
Anti-PDL1/CD274 therapeutic antibody (Pre-made Itanistomig biosimilar,Bispecific Mixed Domains (VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Itanistomig (development code LB-101) is a bispecific antibody targeting PD-L1 (CD274) and CD47. It is developed for solid tumors. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1243-1mg | 1mg | |
| GMP-Bios-INN-1243-10mg | 10mg | |
| GMP-Bios-INN-1243-100mg | 100mg | |
| GMP-Bios-INN-1243-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Itanistomig biosimilar, Bispecific Mixed Domains (VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa), Anti-PDL1/CD274;IAP/CD47 Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody |
| INN Name | Itanistomig |
| Target | PDL1/CD274;IAP/CD47 |
| Format | Bispecific Mixed Domains (VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | 5ggt:HL;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
